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Abstract
Background—Low circulating levels of Coenzyme Q10 (CoQ10) have been associated with
increased cancer incidence and poor prognosis for a number of cancer types, while a recent
prospective study observed a positive association for CoQ10 with breast cancer risk.
Methods—We prospectively examined the association of plasma CoQ10 with breast cancer risk
in a nested case-control study of Chinese women within the Shanghai Women's Health Study
(SWHS). Pre-diagnostic plasma samples were obtained from 340 cases and 653 age-matched
controls and analyzed for total CoQ10.
Results—A borderline significant inverse association for breast cancer incidence with plasma
CoQ10 level was observed using a conditional logistic regression model adjusted for age and age
at first live birth, which became significant after elimination of cases diagnosed within one year of
blood draw (ptrend = 0.03). This association was independent of menopausal status. Plasma CoQ10
levels were also observed to be significantly associated with circulating γ-tocopherol (r = 0.50; p
< 0.0001) and with α-tocopherol (r =0.38; p < 0.0001) levels.
Conclusions—Circulating levels of CoQ10 were generally low in this population and the
observed association with breast cancer risk may be limited to those women with exceptionally
low values.
Impact—This study reports an inverse relationship between circulating CoQ10 and breast cancer
risk, while the only other prospective study of CoQ10 and breast cancer to date found a positive
association. Lower levels of CoQ10 in the SWHS population suggests that the two studies may not
be contradictory and indicates a possible non-linear (U-shaped) association of CoQ10 with risk.
Introduction
Coenzyme Q10 (CoQ10) was isolated and identified fifty years ago as an essential (rate-
limiting) component of the mitochondrial electron transport system leading to ATP
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production and is the only major lipid-soluble antioxidant synthesized by humans (1, 2). All
mammalian cells are capable of synthesizing CoQ10 (or closely related molecules) in a
complex biosynthetic pathway involving the mevalonate pathway (also responsible for
cholesterol and dolichol synthesis) and tyrosine, in a process dependent upon eight essential
vitamins and nutrients (3,4). Mitochondrial energy production is essential for eukaryotic cell
survival and CoQ10 is a key molecule in all energy requiring processes, including
proliferation, apoptosis, angiogenesis, and immune function (5–8), suggesting the potential
for multiple roles in the initiation and progression of cancer. Despite the critical role of
CoQ10 in many cellular functions, its potential relationship with cancer development and
progression has not received appropriate attention. Epidemiological or clinical studies of
plasma or tissue CoQ10 are rare in the literature and have involved limited numbers of
subjects. Folkers, et al. (9), reported reduced circulating total CoQ10 levels in breast cancer
(n=17) and myeloma (n=15) patients. Palan et al., (10) in a cross-sectional study (n=230),
reported an inverse association between cervical intraepithelial neoplasia and cervical cancer
with total circulating CoQ10, as well as with α-tocopherol (αT) and γ-tocopherol (γT).
Rusciani, et al. (11) reported a highly significant association between low plasma total
CoQ10 levels and metastasis and progression in 117 melanoma patients. Recently, in the
largest epidemiologic study to date of CoQ10 involving the Multiethnic Cohort, a positive
association was observed for prediagnostic circulating total CoQ10 and breast cancer risk in
postmenopausal women (12).
Administration of CoQ10 (as the oxidized quinone) to humans has been associated with a
number of favorable clinical outcomes in the treatment of hypertension (13), heart failure
(14), migraines (15), and myopathies associated with statin use (16). In the latter case there
is growing concern for the long-term effects of statin use, resulting in decreased cellular
CoQ10 synthesis and Boudroux, et al. reported a non significant increasing risk for breast
cancer in women as a function of length of time on statins (17). Positive effects have been
reported for CoQ10 in the treatment of breast cancer (18–20), however, these clinical studies
were conducted on small numbers of patients and lacked adequate design.
Cellular and tissue levels of CoQ10 decrease with age, and cellular levels below a critical
threshold are incompatible with life (21). In contrast, plasma levels of CoQ10 are reported by
some to rise as a function of age (22), and are higher in postmenopausal women (23).
Supplemental CoQ10 increases circulating α-T levels in animals (24) and humans (25),
however, the determinants of circulating CoQ10 and its physiological regulation in vivo are
unknown. The objective of the current study was to determine if an association exists
between prediagnostic circulating CoQ10 and breast cancer risk among Chinese women
from the Shanghai Women’s health Study (SWHS).
Materials and Methods
Study Population and Data Collection
The Shanghai Women’s Health Study (SWHS) is a cohort of approximately 75,000 adult
Chinese women between the ages of 40 and 70 in Shanghai, China (26). Subject recruitment
was initiated in June 1997 and completed in May 2000. The cohort is being actively
followed through a combination of record linkage with the files collected in the Shanghai
Cancer Registry and Vital Statistic Unit and a biannual home visit. Nearly all cohort
members were successfully followed, with the response rates for first in-person follow-up
being 99.8% (2000–2002), second 98.7% (2002–2004), and third 96.7% (2004–2007). All
possible matches identified by record linkage were verified by home visits. Medical charts
from the diagnostic hospitals were reviewed to verify the diagnosis, and pathological
characteristics of the tumor were recorded. Breast cancer cases were defined as women for
whom breast cancer was the first cancer diagnosis (ICD-9, code of 174).
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Blood samples were collected from 56,900 subjects (76% of the cohort) during the baseline
survey period. Over an approximately average 7.5 years follow-up, the number of incident
breast cancer cases initially available for analysis was 386 with two controls for each index
case (772) selected randomly from the group of cohort members who were free of cancer at
the time of cancer diagnosis of the index case. The controls were matched to the index case
by age (± 2 years), menopausal status at baseline (yes, no), date of sample collection (± 30
days), time of sample collection (morning or afternoon), time interval after the last meal (± 2
hours), and recent antibiotic use (yes, no). After exclusion of samples with inadequate
plasma available, incomplete matching information, or analytical interference, 340 cases and
653 controls were used in the subsequent analysis. Cases without controls or controls
without cases were deleted from the analysis.
Laboratory Assays
Plasma samples were stored at −75°C, thawed and then aliquoted in a dark room for
analysis. Plasma samples were extracted using hexane after addition of δ-tocopheryl laurate
as an internal standard. The extracts were then stored at −80 °C prior to subsequent analysis
for total CoQ10 by HPLC (Model Spectra, ThermoFisher, San Jose, CA) with pre-column
electrochemical oxidation (guard cell from ESA, Model 5020, Chelmsford, MA) and post-
column UV detection at 275 nm (as described previously 12, 27). The separation was
performed on a Gemini C18 analytical and guard column (150 mm × 2.0 mm, 3 µm and
4mm × 3.0mm, 10 µm, respectively; Phenomenex, Torrance, CA) with a mixture of sodium
acetate trihydrate, glacial acetic acid, 2-propanol, hexane, and methanol. The range of inter-
assay variability was 5 – 7 %. Plasma tocopherols were measured as described previously
(28). Data for the distribution of CoQ10 levels among women was obtained from the current
study and from another study (12) of CoQ10 and breast cancer utilizing the Multiethnic
Cohort (MEC) performed by the same method in the same laboratory and provided by the
authors of that study.
Statistical analysis
Conditional logistic regression, with matched sets as strata, was used to compute odds ratios
(ORs) and 95% confidence intervals (CIs) whereby controls were matched to the index case
by age, menopausal status at baseline, date of sample collection, time of sample collection,
time interval after the last meal, and recent antibiotic use. CoQ10 levels were categorized
into quintiles or quartiles based on the distribution of controls. The third quintile/quartile
was chosen as the reference category to allow for a better comparison with the previous
MEC study, in which the lowest tertile (median CoQ10 = 668 ng/ml) was used as a reference
(12). In addition to matching variables, many potential confounding factors or effect
modifiers have been obtained from survey or other studies (26,29). We conducted analyses
to additionally adjust for age at first child birth, educational achievement, body mass index,
regular physical activity (yes, no), number of full-term pregnancies, age at menarche,
months of breast feeding, smoking status, and alcohol drinking. However, except for age at
first live birth, adjusting for other covariates did not materially change the estimates.
Stratified analyses were conducted by menopausal status and plasma concentration of γT
(≤1948.9; >1948.9). Sensitivity analyses were conducted by excluding those whose blood
samples were collected within one year of cancer diagnosis to reduce the effects possible
pre-clinical cases. P values of <0.05 (2 sided probability) were interpreted as being
statistically significant. Tests for trend were performed by entering the categorical variables
as a continuous variable in the model. Statistical analyses were conducted using SAS
statistical software (version 9.1; SAS Institute, Cary, NC).
Cooney et al. Page 3
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2013 January 15.
$watermark-text
$watermark-text
$watermark-text
Results
Baseline characteristics of patients and matched controls are shown in Table 1. Significant
differences between cases and controls in the direction expected for this population were
observed for education, age at menarche, age at first birth, months of breast feeding, and
family history of breast cancer. Mean and median CoQ10 levels overall were slightly lower
in cases compared to controls (Table 2), however the difference was not statistically
significant. When stratified by menopausal status, postmenopausal women were observed to
have approximately 20% higher average circulating CoQ10 levels compared to
premenopausal women (p = 0.07 among controls).
As shown in Table 3, there was a borderline significant increased risk for all women in the
lowest quintile of plasma CoQ10 compared to the third quintile. After exclusion for cases
diagnosed within one year of blood draw to reduce possible overt pre-clinical cases, a
significant inverse association for plasma CoQ10 with breast cancer risk was observed (p for
trend = 0.03), with significantly increased risk for women in the 1st quintile (OR =1.90; 95%
CI, 1.14–3.16) relative to the third quintile of plasma CoQ10. We found plasma levels of
CoQ10 significantly decreased with older age at first live birth (p<0.01). After including age
at first live birth in the model, the OR (95% confidence interval) for the lowest plasma level
of CoQ10 relative to the third quintile increased from 1.73 (1.07–2.80) to 1.90 (1.14–3.16) in
the analyses excluding cases diagnosed within one year of blood draw. Stratification by
menopausal status (Table 3) revealed similar trends by quartile with women in the lowest
quartile of CoQ10 at elevated risk relative to the third quartile for both pre and
postmenopausal women (p for interaction = 0.40). However, sample size became smaller
and results did not reach significance in stratified analyses. Adjustment for tocopherols did
not change the observed associations.
As shown in Figure 1, plasma CoQ10 levels were highly positively correlated with both
plasma γT (r = 0.50; p < 0.0001) and αT (r = 0.38; p < 0.0001) levels. Circulating γT and
αT levels were not correlated with one another. The distribution of values for plasma CoQ10
for the women analyzed in the SWHS is shown in Figure 2. Comparison data from a similar
study of postmenopausal women in the MEC (12) are plotted for comparison. Significantly
greater CoQ10 levels (approximately 60% higher) were observed in the MEC samples
compared to the SWHS (means ± SD were 1,007 ± 387 and 631 ± 254 ng/ml, respectively, p
< 0.00001). Comparing only post menopausal women, the median CoQ10 level in the MEC
samples was 934 ng/ml compared to 633 ng/ml in the SWHS. In contrast, γT levels in
women from the SWHS (median = 1.95 µg/ml) were nearly twice those observed for women
in the MEC, where a median value of 1.07 µg/ml was reported (12).
Discussion
In the SWHS we observed a significant inverse association for low circulating CoQ10 with
subsequent incidence of breast cancer for women whose breast cancer was diagnosed > one
year after obtaining blood specimens with the highest risk associated with women in the
lowest quintile of circulating CoQ10. The results are consistent with previous reports of
associations of low CoQ10 with increased risk for various cancers and their progression (9–
11). However, a recent prospective study of postmenopausal women utilizing the MEC
found a significant positive association between plasma CoQ10 and risk of breast cancer risk
(12). That study (MEC) utilizing the same analytical laboratory as the current study found
overall significantly higher levels of circulating CoQ10 in a multiethnic American
population compared to the current SWHS study (Figure 2). The median CoQ10 for the
reference tertile in the MEC study (668 ng/ml) was similar to the values for the SWHS
cohort (536–629 ng/ml) where minimal risk was also observed. Significantly increased risk
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for breast cancer was observed for the MEC study at CoQ10 levels >1,000 ng/ml, a level
found in very few women in the SWHS. A possible explanation reconciling these opposing
results is that women at either extreme of CoQ10 may be at increased risk for breast cancer.
The Shanghai cohort encompasses the low end of what may be a U-shaped curve for CoQ10
and the MEC study (12) captures the high end (Figure 2). Both prospective studies appear
consistent in that women with circulating CoQ10 levels in the range of 500–800 ng/ml have
the lowest risk for developing breast cancer. It is unlikely that differences in sample
collection or handling would account for any differences in CoQ10 levels between these two
populations as all CoQ10 was oxidized to the stable quinone prior to analysis and measured
as total CoQ10 by the same method and laboratory.
Because cells are capable of synthesizing CoQ10 endogenously, the question arises as to the
source and physiological meaning of circulating CoQ10. While the source and physiologic
determinants of CoQ10 in the blood are unknown, the close relationship between CoQ10 and
circulating tocopherols may provide some insight. The tocopherols were found to be highly
associated with circulating CoQ10 levels, suggesting either a causal relationship or a
common regulatory mechanism. The mechanism of regulation of circulating tocopherol
levels is also unknown, however, tocopherols, particularly γT, are known to rise in response
to inflammation (30, 31). The strong association between circulating CoQ10 and tocopherols
suggests that CoQ10 level in the blood may also be mediated by systemic and/or localized
inflammation (32). Increased release and/or retention of CoQ10 into the circulatory system
may, like γT, be a response to processes such as inflammation, apoptosis, and cellular
necrosis. Low circulating CoQ10 levels may represent inadequate cellular levels, low
inflammation, enhanced excretion, and/or inadequate immune function. The immune system
can participate in cancer etiology in two opposing manners (33, 34). Chronic inflammation
with an overactive immune system can result in cellular DNA damage and the development
of tumors over time, while an inadequate immune response can lead to decreased immune
surveillance and allow tumors to progress and metastasize.
The SWHS population appears to be quite unique (Table 1) with few participants who were
ever smokers (1.5% for cases, 2.9% for controls), ever drinkers (2.1% for cases, 2.9% for
controls), and current hormone therapy use (3.8% for cases vs 1.4% for controls), indicating
that the population is quite unique relative to Western societies, thus limiting comparisons
with the results of Chai, et al. where considerably higher smoking, alcohol and HRT use
were reported (12). Differences in diet and supplement use may account for the stronger
association observed between γT and CoQ10 in the SWHS. Unlike studies in U.S.
populations, where αT supplementation is more prevalent, no inverse association was
observed between circulating γT and αT in women of the SWHS, which may account for
the stronger association observed for both tocopherols with CoQ10. In the study by Chai, et
al. (12) the positive association between CoQ10 and breast cancer risk was strongest in
women with low γT levels. In contrast, women in the SWHS were found to have generally
higher γT levels and lower CoQ10 values (median γ-tocopherol of 1.95 µg/ml in the SWHS
vs 1.07 µg/ml for the MEC women, 12). As was the case for CoQ10, all tocopherols were
measured in the same laboratory and the lower levels of γT observed in the MEC are likely
related to αT supplementation which significantly lowers γT, but does not affect CoQ10.
In conclusion, the current SWHS study, with relatively larger sample size and longer follow-
up time suggests an inverse association for plasma CoQ10 levels with breast cancer risk in
Chinese women. The opposing relationships observed in the two prospective studies (SWHS
vs the MEC), requires further research to verify the hypothesis that extreme levels of CoQ10
in the plasma are indicators of risk. Additional study into the physiologic significance and
regulation of plasma CoQ10 and its relationship to tocopherols is needed. The present study
does not address the role, if any, of supplemental CoQ10 in the prevention and treatment of
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cancer. Future intervention studies that can assess the physiological effects of
supplementation will be necessary to identify the likely cause and effect relationships and
determine the possible therapeutic benefits or potential harm of supplementation of CoQ10.
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Figure 1.
Association of CoQ10 with tocopherols in plasma. All subjects (n=1,113) were stratified by
plasma CoQ10 into deciles and α- and γ-tocopherol (mean ± SEM) plotted as a function of
the median CoQ10 level for each decile. Correlation coefficients were calculated for the
association of each tocopherol with CoQ10.
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Figure 2.
Distribution of CoQ10 levels found in cases and controls of the Shanghai Cohort:
comparison with postmenopausal women from the Multiethnic Cohort study of CoQ10 and
breast cancer (12). The number of women with CoQ10 values were determined for each 0.2
µg/ml increase in plasma CoQ10 level and plotted as a percentage of the total number of
women analyzed in the SWHS. For comparison, the distribution of plasma CoQ10 levels in
women analyzed for a study of CoQ10 in the Multiethnic Cohort (12) are also shown.
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Table 1
Characteristics of breast cancer cases and controls analyzed for CoQ10 in a nested case-control study within
the Shanghai Women’s Health Study (SWHS), 1997–2006.
Characteristics Cases
(n=340)
Controls
(n=653)
P-
value#
Age at blood draw (years), mean (SD)* 52.4 ± 9.0 52.4 ± 9.0 0.15
Current hormone therapy use, n (%) 13 (3.8) 9 (1.4) 0.04
Education, n (%) <0.01
     Elementary and under 52 (15.3) 151 (23.1)
     Middle school 121 (35.7) 267 (40.9)
     High school 116 (34.2) 168 (25.7)
     College and above 50 (14.7) 67 (10.3)
Body mass index (kg/m2), mean (SD)
     All Women 24.2 ± 3.6 24.4 ± 3.3 0.29
     Premenopausal Women 23.4 ± 3.2 23.6 ± 3.1 0.48
     Postmenopausal Women 25.1 ± 3.7 25.3 ± 3.3 0.54
Physically active, n (%) 122 (35.9) 222 (34.0) 0.67
Nulliparous, n (%) 15 (4.4) 24 (3.7) 0.29
Number of full term pregnancies, mean (SD) 1.7 ± 1.1 1.8 ± 1.1 0.05
Age @ first child birth, mean (SD) 26.3 ± 4.1 25.6 ± 4.2 0.01
Age @ menarche, mean (SD) 14.8 ± 1.8 15.0 ± 1.7 0.03
Months of breast feeding 13.7 ± 15.6 16.3 ± 18.4 <0.01
Smoking status, n (%) 0.39
     Never 335 (98.5) 634 (97.1)
     Former 0 (0) 1 (0.1)
     Current 5 (1.5) 18 (2.8)
Mother or sister with breast cancer, n (%) 14 (4.12) 10 (1.5) 0.01
Alcohol use, n (%) 0.71
     Never 333 (97.9) 634 (97.1)
     Former 1 (0.3) 2 (0.3)
     Current 6 (1.8) 17 (2.6)
Deaths, n (%) 40 (11.7) 20 (3.1) <0.01
Postmenopausal, n (%) 165 (48.5) 320 (49.0) 0.06
*SD Standard deviation
#Conditional logistic regression model for categorical variables or ANOVA test for continuous variables
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Table 2
Comparison of plasma Q10 (ng/mL) levels between breast cancer cases and controls, a nested case-control
study within the Shanghai Women’s Health Study (SWHS), 1997–2006.
Plasma CoQ10
concentration
(ng/mL)
Cases Controls P-
value
All women (340 pairs)
Mean ± SD 605.4 ± 241.0 619.2 ± 185.4 0.25a
Median (25th, 75th) 560.0 (435.0, 728.0) 597.0 (500.0, 714.0) 0.16b
All women with cases diagnosed > 1 year after blood draw (303 pairs)
Mean ± SD 603.7 ± 242.8 622.9 ± 187.4 0.12a
Median (25th, 75th) 553.0 (434.0, 739.0) 597.5 (502.5, 714.5) 0.09b
Premenopausal women (171 pairs)
Mean ± SD 544.6 ± 223.5 554.9 ± 153.0 0.38a
Median (25th, 75th) 508.0 (382.0, 649.0) 554.0 (450.5, 644.0) 0.13b
Postmenopausal women (169 pairs)
Mean ± SD 667.0 ± 243.0 684.3 ± 192.9 0.45a
Median (25th, 75th) 621.0 (494.0, 788.0) 649.5 (550.0, 789.0) 0.55b
a
Paired test using log-transformed values for cases and the average of two matched controls.
b
Paired Wilcoxon signed rank test for cases and the average of two matched controls.
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